Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
about
Macrocyclic histone deacetylase inhibitorsEpigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaTrials with 'epigenetic' drugs: an updateClinical Toxicities of Histone Deacetylase Inhibitors.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaRomidepsin in the treatment of cutaneous T-cell lymphoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerEpigenetics in cancer stem cells.Romidepsin: a novel histone deacetylase inhibitor for cancer.Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.HDAC inhibitor-based therapies: can we interpret the code?Toxicological and metabolic considerations for histone deacetylase inhibitors.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Romidepsin for the treatment of non-Hodgkin's lymphoma.Epigenetic therapy for solid tumors: from bench science to clinical trials.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).Targeting the epigenome for treatment of cancer.
P2860
Q24629065-15EBA993-1E04-4ED7-B09B-B7178F3F8744Q26783014-9C776EDF-7449-407C-BF63-E3E9B69D7103Q27000542-7B8D6553-0126-44FE-8D35-9099196C04A1Q31135325-9602980B-F772-4786-A58B-738C8C97168EQ33390876-BA44E645-CDAA-4FB6-9CBC-FDA74D2D8A02Q33437948-59CDAB33-9DAE-417D-A7F9-36380A8C5EB2Q34171631-61A17048-507A-45D1-A474-2A19CBF6AB63Q34488424-062CE033-1233-4ECC-8454-89FC834DF606Q35042270-487E3AD3-A6EA-4B8F-B5FF-8FA4D97C8F6FQ35186682-AB26E565-1E0B-4D00-A3BD-1F369CE6C674Q35683831-CED2B09F-09F4-4F4F-9E22-FCC1BE53B84CQ35939690-7FD281F6-E3D7-43AB-9B4B-643482DC5877Q36301182-DEFD46F0-C4AB-4335-85E2-D2ACF9F141AFQ37618640-7A785796-262D-482B-A619-20FB3046F463Q37893664-623976C1-EC12-4072-B932-11AF962928E8Q37993589-D48EF2F4-A073-4EEB-B32A-12A9448AD11EQ38058971-C4E3187E-4362-4F90-B105-84A362B282BAQ38071321-1038551D-72B4-4F4A-8FDA-E3040B8BA8B4Q38081988-969F2F1B-7704-4299-BD82-2DA78FC95B9CQ38344675-31D35245-4857-4A55-9236-22DEC949F897Q38455740-1860782B-1B94-4A0A-863A-165D06C2DC64Q38459836-5EF0992F-3C84-4A7B-A930-2F82B3167576Q39248784-C10A5B44-7CD6-4747-8EE0-7E17826CD0C0Q53201323-9A698D5D-9ADB-4563-95CE-B57BF700435D
P2860
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase II trial of romidepsin ( ...... t Oncology Group study (S0336)
@ast
Phase II trial of romidepsin ( ...... t Oncology Group study (S0336)
@en
Phase II trial of romidepsin
@nl
type
label
Phase II trial of romidepsin ( ...... t Oncology Group study (S0336)
@ast
Phase II trial of romidepsin ( ...... t Oncology Group study (S0336)
@en
Phase II trial of romidepsin
@nl
prefLabel
Phase II trial of romidepsin ( ...... t Oncology Group study (S0336)
@ast
Phase II trial of romidepsin ( ...... t Oncology Group study (S0336)
@en
Phase II trial of romidepsin
@nl
P2093
P2860
P1476
Phase II trial of romidepsin ( ...... t Oncology Group study (S0336)
@en
P2093
Cathryn Rankin
Charles D Blanke
James L Abbruzzese
John H Ward
Kevin G Billingsley
Lucas Wong
Paulo M G Hoff
Philip J Gold
Robert A Chapman
Robert P Whitehead
P2860
P2888
P304
P356
10.1007/S10637-008-9190-8
P577
2008-10-22T00:00:00Z
P5875
P6179
1011690571